S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
NASDAQ:CFRX

ContraFect (CFRX) Stock Forecast, Price & News

$1.34
+0.04 (+3.08%)
(As of 05/31/2023 ET)
Compare
Today's Range
$1.30
$1.38
50-Day Range
$0.90
$2.33
52-Week Range
$0.90
$363.20
Volume
69,679 shs
Average Volume
2.59 million shs
Market Capitalization
$2.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$180.75

ContraFect MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
13,388.8% Upside
$180.75 Price Target
Short Interest
Healthy
4.62% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.55mentions of ContraFect in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.75) to ($3.75) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars


CFRX stock logo

About ContraFect (NASDAQ:CFRX) Stock

ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins, and Amurin Peptides. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.

Receive CFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter.

CFRX Stock News Headlines

ContraFect (NASDAQ:CFRX) Downgraded to Sell at StockNews.com
This NASDAQ Stock Is The Amazon Of Medical Supply
This Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More Now
StockNews.com Lowers ContraFect (NASDAQ:CFRX) to Sell
ContraFect (NASDAQ:CFRX) Raised to "Hold" at StockNews.com
This NASDAQ Stock Is The Amazon Of Medical Supply
This Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More Now
What's Going On With ContraFecta Stock Today
ContraFect Co. (NASDAQ:CFRX) Short Interest Update
Why Is ContraFect (CFRX) Stock Down 14% Today?
ContraFect (NASDAQ:CFRX) Upgraded by Maxim Group to Buy
Maxim Group upgrades ContraFect (CFRX) to a Buy
ContraFect (NASDAQ:CFRX) Upgraded by StockNews.com to Sell
See More Headlines
Receive CFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter.

CFRX Company Calendar

Last Earnings
3/31/2023
Today
5/31/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CFRX
Fax
N/A
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$180.75
High Stock Price Forecast
$560.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+13,593.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-65,150,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($2.00) per share

Miscellaneous

Free Float
1,538,000
Market Cap
$2.07 million
Optionable
Not Optionable
Beta
0.44

Key Executives

  • Roger J. Pomerantz
    Chairman, President & Chief Executive Officer
  • Michael Messinger
    Chief Financial Officer
  • Raymond Schuch
    Vice President-Research
  • Gary Woodnutt
    Senior Vice President-Translational Services
  • Matthew Salamone
    Vice President-Human Resources













CFRX Stock - Frequently Asked Questions

Should I buy or sell ContraFect stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ContraFect in the last twelve months. There are currently 2 hold ratings, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CFRX shares.
View CFRX analyst ratings
or view top-rated stocks.

What is ContraFect's stock price forecast for 2023?

4 analysts have issued twelve-month price targets for ContraFect's shares. Their CFRX share price forecasts range from $3.00 to $560.00. On average, they expect the company's stock price to reach $180.75 in the next year. This suggests a possible upside of 13,593.2% from the stock's current price.
View analysts price targets for CFRX
or view top-rated stocks among Wall Street analysts.

How have CFRX shares performed in 2023?

ContraFect's stock was trading at $7.68 at the start of the year. Since then, CFRX stock has decreased by 82.8% and is now trading at $1.32.
View the best growth stocks for 2023 here
.

Are investors shorting ContraFect?

ContraFect saw a increase in short interest in May. As of May 15th, there was short interest totaling 166,000 shares, an increase of 140.9% from the April 30th total of 68,900 shares. Based on an average daily volume of 3,970,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 4.6% of the company's stock are sold short.
View ContraFect's Short Interest
.

When is ContraFect's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our CFRX earnings forecast
.

How were ContraFect's earnings last quarter?

ContraFect Co. (NASDAQ:CFRX) announced its earnings results on Friday, March, 31st. The biotechnology company reported ($16.14) earnings per share (EPS) for the quarter.

When did ContraFect's stock split?

ContraFect's stock reverse split before market open on Tuesday, February 14th 2023. The 1-80 reverse split was announced on Tuesday, February 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What other stocks do shareholders of ContraFect own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Verastem (VSTM), Vaxart (VXRT), Matinas BioPharma (MTNB), VBI Vaccines (VBIV), Novavax (NVAX), Cidara Therapeutics (CDTX), Gilead Sciences (GILD) and Dynavax Technologies (DVAX).

What is ContraFect's stock symbol?

ContraFect trades on the NASDAQ under the ticker symbol "CFRX."

Who are ContraFect's major shareholders?

ContraFect's stock is owned by a number of institutional and retail investors. Top institutional investors include Armistice Capital LLC (5.49%), Acadian Asset Management LLC (3.26%), State Street Corp (1.74%), Virtu Financial LLC (0.86%), Simplex Trading LLC (0.00%) and FNY Investment Advisers LLC (0.00%).
View institutional ownership trends
.

How do I buy shares of ContraFect?

Shares of CFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ContraFect's stock price today?

One share of CFRX stock can currently be purchased for approximately $1.32.

How much money does ContraFect make?

ContraFect (NASDAQ:CFRX) has a market capitalization of $2.07 million. The biotechnology company earns $-65,150,000.00 in net income (profit) each year or ($88.03) on an earnings per share basis.

How can I contact ContraFect?

ContraFect's mailing address is 28 WELLS AVENUE 3RD FLOOR, YONKERS NY, 10701. The official website for the company is www.contrafect.com. The biotechnology company can be reached via phone at (914) 207-2300 or via email at mmessinger@contrafect.com.

This page (NASDAQ:CFRX) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -